Who
Leslie Norwalk V
Director
Company insider
Files Form 4 as: Director, Neurocrine Biosciences; Director, Arvinas; Director, CVS Health; Director, Globus Medical; Director, ModivCare; Director, Nuvasive; Director, Centene; Director, Magellan Health.
In numbers
- Trades disclosed
- 150
- Buys
- 0
- Sells
- 11
- Bought
- $0
- Sold
- $5.6M
- Companies
- 11
- Companies where not an officer
- 11
- First trade
- 24 Oct 2011
- Last trade
- 29 Jul 2026
- Last filed
- 30 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Jul 2026filed 30 Jul 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | $117K842 at $139.43 | filing |
| 29 Jul 2026filed 30 Jul 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —842 at $0.00 | filing |
| 29 Jul 2026filed 30 Jul 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —842 at $0.00 | filing |
| 29 Jul 2026filed 30 Jul 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | $117K842 at $139.43 | filing |
| 28 Jul 2026filed 30 Jul 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $228K1,250 at $182.01 | filing |
| 28 Jul 2026filed 30 Jul 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $228K1,250 at $182.01 | filing |
| 24 Jun 2026filed 26 Jun 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —15,527 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,714 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,714 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —15,527 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $210K1,250 at $168.06 | filing |
| 4 Jun 2026filed 8 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $210K1,250 at $168.06 | filing |
| 27 May 2026filed 29 May 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —1,284 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —2,624 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —1,284 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —2,624 at $0.00 | filing |
| 21 May 2026filed 21 May 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | —1,659 at $0.00 | filing |
| 21 May 2026filed 21 May 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,659 at $0.00 | filing |
| 21 May 2026filed 21 May 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,659 at $0.00 | filing |
| 21 May 2026filed 21 May 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | —1,659 at $0.00 | filing |
News
Contrasting Neurocrine Biosciences (NASDAQ:NBIX) and Perrigo (NYSE:PRGO)NBIX · dailypolitical.com · 10 Oct 2026Comparing Lifeward (NASDAQ:LFWD) and Globus Medical (NYSE:GMED)GMED · themarketsdaily.com · 6 Oct 2026
0 headlines in the last 90 days name Leslie Norwalk V; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.